VXRT inventory forecast 2025 refers back to the predicted efficiency of the inventory of Vaxart, Inc. (VXRT) within the 12 months 2025. Inventory forecasts try and predict the long run worth of a inventory primarily based on numerous elements akin to the corporate’s monetary efficiency, business traits, and general financial situations.
VXRT is a clinical-stage biotechnology firm centered on creating oral vaccines for infectious ailments. The corporate’s lead product candidate is VXA-CoV2-1, an oral vaccine for COVID-19. Vaxart has additionally developed oral vaccines for norovirus, seasonal influenza, and respiratory syncytial virus (RSV).
